Selecta Biosciences

Selecta Biosciences is a bio-pharmaceutical company that is known for developing therapies and treatments for unwanted immune responses. The company was founded by Omid Farokhzad in 2008, in Watertown, Massachusetts, United States.

Creating a generation of nanoparticle immunomodulatory drugs that can treat or prevent certain diseases by restoring the body's natural tolerances to autoimmune diseases, and inducing tolerance to highly immunogenic proteins is what their therapeutic programs are designed for. Their program, ImmTOR, is both a gene and gout therapy program. With gout, ImmTOR is meant to be co-administered with the company's proprietary uricase named pegadricase in order to power efficacy in chronic refractory gout.

The program can also be used to mitigate the immunogenicity to AAV gene therapies and re-dose gene therapy. Boosting and maintaining transgene expression over time for patients that had genetic metabolic diseases since childhood is one of the purposes for ImmTOR. The AAV gene therapy is introduced to the dendritic cell, which sends a guided message to a naive T-cell. This can split into a helper T-cell or a B-cell, and both repeat AAV gene therapy efficacy.